Abstract:Neurofibromatosis type 2(NF2) is an autosomal-dominant tumor predisposition syndrome that affects the whole neuro-axis and causes various neurological symptoms decreasing the quality of life throughout the patient's lifespan. However, due to the diversity of related diseases and the complexity of treatment, there are many cases in which only partial treatments are performed, the timing of the treatment is missed, and inappropriate treatment modality selection is made despite the intervention of many clinicians. Therefore, to increase the overall understanding of the disease, the single-institution experience was analyzed. Between 1998 and 2022, a total of 80 patients who clinically suspected NF2 visited our Brain Tumor Center. After excluding the patients with follow-up loss, the remaining 48 patients were finally analyzed. The patient's symptoms, diagnosis process, treatment process, and outcomes were analyzed. The average age at the time of symptom onset was 31.0(2-63) year-old. Hearing impairment was the major primary symptom(46.8%) among the patients. Five patients(10.9%) had family history of NF2. Thirty-five patients(76.1%) was clinically diagnosed as a NF2 for the bilateral vestibular schwannomas, and 34 patients(73.9%) had intracranial meningiomas, and 37 patients(80.4%) had spinal lesions at the time of diagnosis. Eleven patients were genetically confirmed as NF2. For vestibular schwannomas, 16 patients had surgical resection and 20 patients took gamma-knife surgery as a primary or secondary treatment. For intracranial meningiomas, 16 patients had surgical resection, 13 patients took gamma-knife surgery, and 15 patients took conventional radiation therapy as a primary or secondary treatment. Ventriculo-peritoneal shunt due to increased intracranial pressure was performed in 4 patients(8.7%). For spinal lesions, 16 patients had surgical resection. NF2 is a disease group requiring a multidisciplinary team approach. The key to treatment is to set and implement a treatment sequence and method tailored to each patient. For this, an overall understanding of the disease and the treatment options is essential.

Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions

Current progress in genomics and targeted therapies for neurofibromatosis type 2

The genetic landscape and possible therapeutics of neurofibromatosis type 2

[Gene therapy strategies and prospects for neurofibromatosis type 1]

Molecular Insights and Therapeutic Avenues

NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

Individualized Diagnosis and Treatment of Neurofibromatosis Type Ⅱ Guided by Molecular Genetic Analysis

An update on the CNS manifestations of neurofibromatosis type 2

Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis

Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and Its Prognostic Impact on Tumour Growth Patterns

Schwannomatosis: a New Member of Neurofibromatosis Family.

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

Qlti-13. A Review Of The Best Treatment Strategy For Neurofibromatosis Type 2 Patients Through A Single-Center Retrospective Study: How To Orchestrate Multimodal Treatment Options

[Progress in neurosurgical treatment of neurofibromatosis type 1]

Translating current basic research into future therapies for neurofibromatosis type 1

New classification and approaches to the treatment of schwannomatosis

Therapeutic advances in treatment of patients with neurofibromatosis type 1 and type 2

Novel Patient-Derived Xenograft and Cell Line Models for Therapeutic Screening in NF2-associated Schwannoma.

[NF2: ocular, neural and genetic manifestations]

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2